Cargando…
Immunogenicity and early clinical outcome after two or three doses of SARS-CoV-2 mRNA-BNT162b2 vaccine in actively treated cancer patients: results from the prospective observational Vax-On-Third study
| Autores principales: | , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
European Society for Medical Oncology. Published by Elsevier Ltd.
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8993701/ https://www.ncbi.nlm.nih.gov/pubmed/35413398 http://dx.doi.org/10.1016/j.annonc.2022.04.002 |
| _version_ | 1784683955684900864 |
|---|---|
| author | Nelli, F. Giannarelli, D. Fabbri, A. Silvestri, M.A. Berrios, J. R. Giron Virtuoso, A. Marrucci, E. Schirripa, M. Mazzotta, M. Onorato, A. Panichi, V. Topini, G. Pessina, G. Natoni, F. Signorelli, C. Chilelli, M.G. Primi, F. Ruggeri, E.M. |
| author_facet | Nelli, F. Giannarelli, D. Fabbri, A. Silvestri, M.A. Berrios, J. R. Giron Virtuoso, A. Marrucci, E. Schirripa, M. Mazzotta, M. Onorato, A. Panichi, V. Topini, G. Pessina, G. Natoni, F. Signorelli, C. Chilelli, M.G. Primi, F. Ruggeri, E.M. |
| author_sort | Nelli, F. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-8993701 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | European Society for Medical Oncology. Published by Elsevier Ltd. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-89937012022-04-11 Immunogenicity and early clinical outcome after two or three doses of SARS-CoV-2 mRNA-BNT162b2 vaccine in actively treated cancer patients: results from the prospective observational Vax-On-Third study Nelli, F. Giannarelli, D. Fabbri, A. Silvestri, M.A. Berrios, J. R. Giron Virtuoso, A. Marrucci, E. Schirripa, M. Mazzotta, M. Onorato, A. Panichi, V. Topini, G. Pessina, G. Natoni, F. Signorelli, C. Chilelli, M.G. Primi, F. Ruggeri, E.M. Ann Oncol Letter to the Editor European Society for Medical Oncology. Published by Elsevier Ltd. 2022-07 2022-04-09 /pmc/articles/PMC8993701/ /pubmed/35413398 http://dx.doi.org/10.1016/j.annonc.2022.04.002 Text en © 2022 European Society for Medical Oncology. Published by Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
| spellingShingle | Letter to the Editor Nelli, F. Giannarelli, D. Fabbri, A. Silvestri, M.A. Berrios, J. R. Giron Virtuoso, A. Marrucci, E. Schirripa, M. Mazzotta, M. Onorato, A. Panichi, V. Topini, G. Pessina, G. Natoni, F. Signorelli, C. Chilelli, M.G. Primi, F. Ruggeri, E.M. Immunogenicity and early clinical outcome after two or three doses of SARS-CoV-2 mRNA-BNT162b2 vaccine in actively treated cancer patients: results from the prospective observational Vax-On-Third study |
| title | Immunogenicity and early clinical outcome after two or three doses of SARS-CoV-2 mRNA-BNT162b2 vaccine in actively treated cancer patients: results from the prospective observational Vax-On-Third study |
| title_full | Immunogenicity and early clinical outcome after two or three doses of SARS-CoV-2 mRNA-BNT162b2 vaccine in actively treated cancer patients: results from the prospective observational Vax-On-Third study |
| title_fullStr | Immunogenicity and early clinical outcome after two or three doses of SARS-CoV-2 mRNA-BNT162b2 vaccine in actively treated cancer patients: results from the prospective observational Vax-On-Third study |
| title_full_unstemmed | Immunogenicity and early clinical outcome after two or three doses of SARS-CoV-2 mRNA-BNT162b2 vaccine in actively treated cancer patients: results from the prospective observational Vax-On-Third study |
| title_short | Immunogenicity and early clinical outcome after two or three doses of SARS-CoV-2 mRNA-BNT162b2 vaccine in actively treated cancer patients: results from the prospective observational Vax-On-Third study |
| title_sort | immunogenicity and early clinical outcome after two or three doses of sars-cov-2 mrna-bnt162b2 vaccine in actively treated cancer patients: results from the prospective observational vax-on-third study |
| topic | Letter to the Editor |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8993701/ https://www.ncbi.nlm.nih.gov/pubmed/35413398 http://dx.doi.org/10.1016/j.annonc.2022.04.002 |
| work_keys_str_mv | AT nellif immunogenicityandearlyclinicaloutcomeaftertwoorthreedosesofsarscov2mrnabnt162b2vaccineinactivelytreatedcancerpatientsresultsfromtheprospectiveobservationalvaxonthirdstudy AT giannarellid immunogenicityandearlyclinicaloutcomeaftertwoorthreedosesofsarscov2mrnabnt162b2vaccineinactivelytreatedcancerpatientsresultsfromtheprospectiveobservationalvaxonthirdstudy AT fabbria immunogenicityandearlyclinicaloutcomeaftertwoorthreedosesofsarscov2mrnabnt162b2vaccineinactivelytreatedcancerpatientsresultsfromtheprospectiveobservationalvaxonthirdstudy AT silvestrima immunogenicityandearlyclinicaloutcomeaftertwoorthreedosesofsarscov2mrnabnt162b2vaccineinactivelytreatedcancerpatientsresultsfromtheprospectiveobservationalvaxonthirdstudy AT berriosjrgiron immunogenicityandearlyclinicaloutcomeaftertwoorthreedosesofsarscov2mrnabnt162b2vaccineinactivelytreatedcancerpatientsresultsfromtheprospectiveobservationalvaxonthirdstudy AT virtuosoa immunogenicityandearlyclinicaloutcomeaftertwoorthreedosesofsarscov2mrnabnt162b2vaccineinactivelytreatedcancerpatientsresultsfromtheprospectiveobservationalvaxonthirdstudy AT marruccie immunogenicityandearlyclinicaloutcomeaftertwoorthreedosesofsarscov2mrnabnt162b2vaccineinactivelytreatedcancerpatientsresultsfromtheprospectiveobservationalvaxonthirdstudy AT schirripam immunogenicityandearlyclinicaloutcomeaftertwoorthreedosesofsarscov2mrnabnt162b2vaccineinactivelytreatedcancerpatientsresultsfromtheprospectiveobservationalvaxonthirdstudy AT mazzottam immunogenicityandearlyclinicaloutcomeaftertwoorthreedosesofsarscov2mrnabnt162b2vaccineinactivelytreatedcancerpatientsresultsfromtheprospectiveobservationalvaxonthirdstudy AT onoratoa immunogenicityandearlyclinicaloutcomeaftertwoorthreedosesofsarscov2mrnabnt162b2vaccineinactivelytreatedcancerpatientsresultsfromtheprospectiveobservationalvaxonthirdstudy AT panichiv immunogenicityandearlyclinicaloutcomeaftertwoorthreedosesofsarscov2mrnabnt162b2vaccineinactivelytreatedcancerpatientsresultsfromtheprospectiveobservationalvaxonthirdstudy AT topinig immunogenicityandearlyclinicaloutcomeaftertwoorthreedosesofsarscov2mrnabnt162b2vaccineinactivelytreatedcancerpatientsresultsfromtheprospectiveobservationalvaxonthirdstudy AT pessinag immunogenicityandearlyclinicaloutcomeaftertwoorthreedosesofsarscov2mrnabnt162b2vaccineinactivelytreatedcancerpatientsresultsfromtheprospectiveobservationalvaxonthirdstudy AT natonif immunogenicityandearlyclinicaloutcomeaftertwoorthreedosesofsarscov2mrnabnt162b2vaccineinactivelytreatedcancerpatientsresultsfromtheprospectiveobservationalvaxonthirdstudy AT signorellic immunogenicityandearlyclinicaloutcomeaftertwoorthreedosesofsarscov2mrnabnt162b2vaccineinactivelytreatedcancerpatientsresultsfromtheprospectiveobservationalvaxonthirdstudy AT chilellimg immunogenicityandearlyclinicaloutcomeaftertwoorthreedosesofsarscov2mrnabnt162b2vaccineinactivelytreatedcancerpatientsresultsfromtheprospectiveobservationalvaxonthirdstudy AT primif immunogenicityandearlyclinicaloutcomeaftertwoorthreedosesofsarscov2mrnabnt162b2vaccineinactivelytreatedcancerpatientsresultsfromtheprospectiveobservationalvaxonthirdstudy AT ruggeriem immunogenicityandearlyclinicaloutcomeaftertwoorthreedosesofsarscov2mrnabnt162b2vaccineinactivelytreatedcancerpatientsresultsfromtheprospectiveobservationalvaxonthirdstudy |